US Edition
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum ...
The lawsuit claims Novo Nordisk overstated growth potential and misled investors, causing a 21.83% stock price drop after lowered sales and profit outlook announcement.
- On July 28, 2025, Rosen Law Firm filed a class action lawsuit against Novo Nordisk A/S, alleging false statements and concealment of material adverse facts during May 7, 2025, to July 28, 2025.
- Amid ambitious forecasts, the company downplayed the impact of the personalization exception to compounded GLP-1 exclusion and overstated market potential, according to the lawsuit.
- Following the lowered outlook announcement, Novo Nordisk A/S's share price fell from $69 to $53.94, a decline of about 21.83%.
- Investors who purchased Novo Nordisk securities during the class period may be entitled to compensation through a contingency fee arrangement, as damages emerged when true details entered the market.
- With a history of record settlements, Rosen Law Firm, a global investor rights law firm, secured over $438 million for investors in 2019 and was named a Titan of Plaintiffs' Bar in 2020.
29 Articles
29 Articles
Hastings Tribune
Eagle-TribuneBragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum ...
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT),…
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm - Novo Nordisk (NYSE:NVO), Altimmune (NASDAQ:ALT)
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Addi…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
